Processa Pharmaceuticals, Inc. (PCSA) · Nov 5, 2026 · Other events
Stockholder letter — 2.8M current shares vs 309.3M as-converted
Processa’s stockholder letter recaps its Vidya-led immunology pivot, clinical roadmap and funding while highlighting the much larger post-conversion share count.
Processa is no longer primarily a legacy-drug developer: after acquiring Vidya Therapeutics in July 2026, it is now a clinical-stage immunology company built around VT-7208, with roughly $200 million of financing intended to fund Phase 2 work through the second half of 2029. The FDA’s CSU trial clearance, the Generian FcRn collaboration and the broader strategic pivot were already disclosed on October 29, so this filing is mainly shareholder communication rather than a new operating milestone.
The letter confirms execution, but does not advance the story beyond what was already public. It repeats the plan to pursue Phase 2 proof-of-concept studies in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis, alongside a preclinical FcRn program. The meaningful clinical update—FDA clearance of the CSU IND—was announced before this filing, making the November 5 letter confirmation rather than a fresh catalyst. 〔0〕
The main value of the filing is clarifying the post-transaction capital structure. The 2.8 million common shares currently trading are dwarfed by 306.5 million Series A preferred shares on an as-converted basis, for 309.3 million shares in total. That is not new dilution created by this filing; it is a clearer presentation of dilution already embedded in the July transaction and previously reflected in the company’s filings. 〔1〕
| Capitalization | Current | As-converted |
|---|---|---|
| Common shares outstanding (Expected capitalization) | 2.8M | |
| Series A preferred (Expected capitalization) | 306.5M | |
| Total common shares (Expected capitalization) | 309.3M |
The near-term corporate work is shareholder approval, not new science. Processa is soliciting votes on preferred-share conversion, a reverse split tied to Nasdaq compliance, equity-plan capacity and other public-company matters. The first proxy package was already filed on October 22, while the second meeting’s definitive materials were still forthcoming; the letter therefore organizes an already disclosed approval process rather than changing the clinical outlook. The company’s investor calendar lists a November 30, 2026 special meeting.
Bottom line: This filing makes the new Processa story easier to understand, especially its enormous as-converted share count, but it does not materially change the business or expectations. The next real information will come from shareholder votes and clinical execution, not this letter itself.
Separate stockholder votes and Phase 2 trial milestones
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!